USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis Read more about USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis
Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI® Read more about Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®
Evoke Pharma Reports Record Third Quarter 2022 Financial Results Read more about Evoke Pharma Reports Record Third Quarter 2022 Financial Results
Evoke Pharma to Report Third Quarter Results on November 9, 2022 Read more about Evoke Pharma to Report Third Quarter Results on November 9, 2022
Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting Read more about Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting
Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI Read more about Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI
GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award Read more about GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award
Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference Read more about Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference
Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution Read more about Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution
Evoke Pharma Reports Second Quarter 2022 Financial Results Read more about Evoke Pharma Reports Second Quarter 2022 Financial Results